TG Therapeutics (NASDAQ:TGTX) Reaches New 12-Month High – Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $47.93 and last traded at $48.48, with a volume of 493673 shares traded. The stock had previously closed at $43.37.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Finally, Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Stock Up 3.1%

The firm’s 50 day moving average price is $38.06 and its two-hundred day moving average price is $32.99. The company has a market cap of $7.36 billion, a P/E ratio of 16.80 and a beta of 1.68. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business’s revenue was up 69.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS. Equities research analysts anticipate that TG Therapeutics, Inc. will post 1.51 EPS for the current fiscal year.

Institutional Trading of TG Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S bought a new stake in TG Therapeutics during the 3rd quarter valued at $25,000. Optiver Holding B.V. increased its stake in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares in the last quarter. Bessemer Group Inc. increased its stake in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in shares of TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.